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Soluble guanylate cyclase (sGC) is a haem containing enzyme that regulates cardiovascular homeostasis
and multiple mechanisms in the central and peripheral nervous system. Commonly used inhibitors of
sGC activity act through oxidation of the haemmoiety, however they also bind haemoglobin and this lim-
its their bioavailability for in vivo studies. We have discovered a new class of small molecule inhibitors of
sGC and have characterised a compound designated D12 (compound 10) which binds to the catalytic
domain of the enzyme with a KD of 11 lM in a SPR assay.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The heterodimeric enzyme soluble guanylate cyclase (sGC) is an
endogenous receptor for nitric oxide (NO). NO binds to a haem
prosthetic group resulting in a conformational change which acti-
vates the enzyme. Upon activation, sGC converts guanosine
triphosphate (GTP) into cyclic guanosine monophosphate (cGMP).
NO-induced activation of sGC is key to maintaining cardiovascular
homeostasis and in the brain, NO—sGC acts as a neurotransmitter—
receptor system.1–3
NO-induced signalling has been implicated in the modulation of
synaptic transmission and to act in long-term potentiation, one of
the major cellular mechanisms that underlie the processes of
learning and memory.4 In rats, high cGMP levels promote neural
stem cells differentiation to neurons whilst reduced cGMP levels
promote differentiation to non-neuronal (mainly glial) cells, which
consequently leads to impaired cognitive function.5
NO can mediate neurotoxicity and cause neuronal cell death.
The rapid on–off-kinetics and desensitization profile of NO, com-
bined with variations in the rate of cGMP breakdown, provide fun-
damental mechanisms for shaping cellular cGMP responses and isimportant in decoding NO signals under physiological and patho-
logical conditions.6 The neurotransmitter is associated with patho-
genic mechanisms involved in multiple neurodegenerative
diseases, including Parkinson’s Disease (PD).7 The NO—sGC system
is also involved in the etiology of migraine.8 Recent research has
suggested the involvement of NO in PD is due to activation of
sGC. Disruption of striatal NO-sGC-cGMP signalling cascades
resulted in profound changes in behavioural, electrophysiological,
and molecular responses to pharmacological manipulations of
dopamine and glutamate transmission.9 Studies performed in ani-
mal models of PD with a sGC inhibitor, ODQ 1 (Fig. 1), have shown
that the enzyme could be a new drug target for restoring basal
ganglia dysfunction and attenuating motor symptoms associated
with PD.9 ODQ 1 has been widely used to study the function of
the NO-sGC-cGMP signal transduction pathway and it has been a
valuable tool to distinguish signalling events mediated by sGC
from those involving other nucleotide cyclases.10 The small mole-
cule binds to the ferrous haem in the b-subunit of the enzyme,
yielding ferric haem which cannot bind NO.11,12 Haem-binding
compounds such as ODQ 1 and its 8-bromo-analogue NS2028,
show activity against other haem containing proteins as such as
haemoglobin, albeit at high concentrations.13,14 ODQ may also
not be able to block cGMP signalling in all circumstances.15
Other known ways of inhibiting sGC activity include block of the
catalytic site with ATP and GTP analogues16–20 though these have
weak inhibitory potency. Inhibitors such as LY-83583 act indirectly
by generating superoxide which reacts rapidly with NO.16
Previously we demonstrated that surface plasmon resonance
(SPR) allied to biochemical screening was an effective way of
Figure 1. Chemical structures of sGC inhibitor ODQ 1, Lamotrigine 2, and analogues
Sipatrigine 3 and 4.
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small molecule inhibitor of sGC, which does not act through oxida-
tion of the haem.
2. Results
2.1. In silico similarity searching and screening
In the course of studies in our laboratory we observed activa-
tion of sGC with the anti-epileptic drug lamotrigine 2 and inhibi-
tion with lamotrigine analogues sipatrigine 3 and 4, all at low
millimolar concentrations (data not shown) (Fig. 1). These com-
pounds were used as the starting point for a screening study to find
new inhibitors of sGC. The strategy was to conduct several rounds
of similarity searching and screening to identify the best inhibitors.
Some synthetic studies were conducted on the best hit to explore
the structure–activity relationships.
Virtual screening was performed by similarity searches using
MACCS fingerprints at 85% and 75% Tanimoto of commercial
libraries and the selected compounds were screened at 100 lM
against purified bovine lung sGC using diethylamine NONOate
(30 nM) as the NO donor. Enzyme activity was determined by
measuring cGMP production using a standard cGMP [3H] radioim-
munoassay.21,22 The initial structure searched (Fig. 2, substructure
A) resulted in circa 500 structures, out of which 16 compounds
were selected based upon diversity, molecular size, and availabil-
ity. Compounds 5 and 6 showed inhibition of enzyme activity by
51% at 100 lM. Subsequent searches of substructures B and C
resulted in the identification of [1,2,5]oxadiazolo[3,4-b]pyrazinesFigure 2. Virtual screening. Chemical structures of virtually searched substructures A
correspond to the % inhibition of sGC activity at 100 lM compound.7 and 8, and N2,N3-diphenylquinoxaline-2,3-diamines 9 and 10
(designated D12) as inhibitors of sGC (Fig. 2).2.2. Chemistry and structure activity studies
The hit compound 10 is formed of a quinoxaline scaffold with a
nitro group in the 6-position of the heterocycle, and joined to two
phenols via secondary amine linkers. A small set of analogues was
synthesised to explore the binding role of the substituents, focus-
ing on the nitro group and the phenols (Table 1).
Compound 10 and analogues 14–28 were synthesised via
nucleophilic aromatic displacement using commercially available
anilines and 2,3-dichloro-quinoxalines 12 when possible. In
other cases 2,3-dichloroquinoxalines 12 were obtained via a
known two-step synthesis, starting with the condensation of 1,2-
diamines with oxalic acid.23 The resulting 2,3-dihydroxyquino-
xalines 11 were chlorinated with thionyl chloride and a catalytic
amount of DMF. The carboxamide substituted quinoxaline 13
was obtained after amidation of the carbonyl chloride intermediate
12a (Scheme 1).
Reduction of the nitro group in compound 10 was successfully
achieved using tin(II) chloride in the presence of sodium borohy-
dride to give compound 29 (Scheme 2).
We have previously described a surface plasmon resonance-
based assay for the detection of binding of small molecules to
full-length sGC and a smaller construct of the catalytic domain
(sGCcat).24 This assay was used to measure the binding of the com-
pounds to sGCcat.24 In general, compounds with hydroxyls on the
anilino phenyl rings (10, 14, 20, 21, 23–26, 28, 29) showed higher
binding to the enzyme, suggesting they might be involved in
hydrogen bonding. The position of the hydroxyl group can be chan-
ged whilst retaining binding strength and activity. However, other
groups such as acetamide 17, 18, methoxy 15, or fluoro 19, ren-
dered the compound biochemically inactive and reduced its bind-
ing strength.
The electron-withdrawing nitro group commonly presents as a
challenge in drug design. Nitro-aromatics are commonly associ-
ated with toxicity, but identifying suitable replacements has pro-
ven difficult.25 A series of 6-substituted-2,3-dichloroquinoxalines
was synthesised. Further modifications included the reduction of
the nitro group to a primary amine, and the conversion of an
acyl chloride into an amide (Schemes 1 and 2). Changes in the–C and the most active compounds 5–10 of each series. The values in brackets
Table 1
% inhibition of sGC and SPR binding level of synthesised analogues of compound 10 to
sGCcat
N
N
NH
NHR1
R2
R2
R3
R3
Compd
number
R1 R2 R3 sGCcat (SPR)
binding
norm. resp.
(RU)
sGC activity%
inhibition at
100 lM
10 NO2 OH H 14.4 ± 1.7 56.2 ± 22.4
14 NO2 H OH 11.6 ± 0.8 41.4
15 NO2 OCH3 H 1.0 ± 0.3 —
16 NO2 H H 2.6 ± 0.2 —
17 NO2 NHCOCH3 H 0.8 ± 0.3 —
18 NO2 H NHCOCH3 3.0 ± 1.0 —
19 NO2 F H 1.9 ± 1.8 —
20 H OH H 12.4 ± 0.1 —
21 CF3 OH H 6.4 ± 0.5 44.4
22 CF3 H OH 3.0 ± 0.5 21.1
23 CN OH H 4.5 ± 2 —
24 CN H OH 10.5 ± 0.5 —
25 Cl OH H 9.7 ± 0.5 —
26 Cl H OH 9.0 ± 0.4 —
27 CONHCH3 OH H 1.1 ± 0.3 —
28 CONHCH3 H OH 9.6 ± 0.3 —
29 NH2 OH H 9.9 ± 0.2 —
Scheme 2. Reduction of nitro group to a primary amine. (a) NaBH4, SnCl22H2O,
EtOH, reflux, 2 h.
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show high or medium binding to the receptor, but poor or null
inhibition of its activity, with the exception of the trifluoromethyl
compounds 21 and 22. Removal of the nitro group (compound
20) showed only a small decrease in binding, but showed no signif-
icant inhibition of the enzyme. This would suggest that binding
of the compounds is not greatly influenced by the group in the
6-position of the quinoxaline, but this is however required for
activity. Insertion of amine 29, chloro 25, 26, and nitrile 23, 24
groups also resulted in compounds which bind to the receptor
but do not inhibit the enzyme activity.Scheme 1. General synthetic route to compounds 10 and 14–29. (a) 4 N HCl, reflux, 2 h;
DCM, rt, 24 h.2.3. Molecular modelling
A possible binding mode was investigated by molecular mod-
elling, using the available crystal structure of sGCcat (pdb code
3uvj). Compound 10 was docked into the allosteric site of sGC
and possible binding modes were analysed based on their
Goldscore fitness. Most binding modes are similarly docked at
the interface of the two subunits. The docking poses show four
key interactions with the receptor: one oxygen of the nitro group
may act as H-bond acceptor for two backbone NHs, being the only
interaction with residues of the b-subunit; the two NH groups
attached to the quinoxaline may act as H-bond donors for the side
chain of a glutamic acid; one or two OH groups can act as a H-bond
donors; and a p–cation interaction is suggested between a charged
lysine and one of the aromatic rings. In addition, the lysine and
arginine residues present in the site could show p–cation interac-
tions with other aromatic rings of the ligand (Fig. 3).
2.4. Biological and biophysical characterisation of compound 10
The activity of compound 10 on sGC was tested in the presence
of increasing concentrations of GTP (Fig. 4a) and NO (Fig. 4b).
Concentration–response curves did not show appreciable variation
amongst different conditions, suggesting activity of the compound
is not through competition with NO or GTP. Activation of sGC can
also be induced by the haem-mimetic drug cinaciguat in the
absence of NO.26 Cinaciguat binds to the haem-deficient protein,
simulating the NO-activated state.
Compound 10 was capable of inhibiting cGMP production after
enzyme activation with cinaciguat, further demonstrating that its
mechanism of action is not NO-dependent. Activity against
membrane-bound GCs was measured using purified rat lung(b) SOCl2, DMF, reflux, 2 h; (c) aniline, NMP, 150 C, 5 min, lW; (d) CH3NH2, EtOH,
Figure 3. Docking of compound 10 into the allosteric binding site of sGC. (a)
Cartoon representation of compound 10 docked at the interface of the two subunits
of the catalytic domain of sGC (PDB code 3uvj), in which the a-subunit is coloured
green and the b-subunit coloured orange; (b) representation of the ligand
interaction between the compound and the residues of sGC.
Figure 4. Biochemical characterisation of compound 10 activity. Compound 10 inhibited
(50, 200, 1000 lM) and clamped NO concentrations at (a) 0.3 nM and (b) 10 nM.
Table 2
sGC activity of compound 10
GC activator Compound 10
IC50 (lM) ± SE
Hill slope
Cinaciguat 1 lM 37 ± 40 4
20 nM 25 ± 4 4
ANP 1 lM 25 ± 13 1
10 nM 21 ± 3 2
Basal 15 ± 2 2
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activated sGC. cGMP generation was measured after stimulation
with
atrial natriuretic peptide and compound 10 showed inhibition of
pGC-generated cGMP, indicating an action through the catalytic
domain of the enzyme (Table 2).
The ability of compound 10 to inhibit sGC in tissues was
explored using NMDA-stimulated cGMP production in cerebellar
slices, which depends on NO formation. Rat cerebellar slices were
pre-incubated with compound 10 then treated with NMDA.
Compound 10 inhibited the ensuing cGMP generation almost com-
pletely at 100 lM and to a lesser extent at 1 lM (Fig. 5).
The binding affinity of compound 10 to sGCcat was explored in
detail using SPR, and suggests a 1:1 interaction between the com-
pound and the dimer, with a calculated KD of 11.4 ± 1.8 lM (Fig. 6).
Further characterisation with full-length enzyme gave a KD of
19.4 ± 2.1 lM.
3. Discussion
The sGC heterodimer is composed of a a-subunit and a shorter
b-subunit which presents in the N-terminal the prosthetic haem
group bound to histidine-105.27 Each subunit is composed of a
haem-nitric oxide binding domain, a PAS-like domain, a coiled-
coil bundle, and the C-terminal catalytic domain where turnover
of GTP into cGMP occurs.28 The catalytic domain of sGC shows
two sites at the interface of the a- and b-subunits that can accom-
modate small molecules: the GTP binding site, and an allosteric
regulatory binding site.29–31 The two sites are different, and small
molecules can bind to one or to both sites, thus showing a 1:1 or
1:2 binding ratio. We have previously shown by surface plasmon
resonance (SPR) that ATP binds to both sites and may inhibit sGC
activity via competition with GTP, highlighting the potential for
allosteric regulation of the enzyme.24 GC domains are also present
in the membrane-bound natriuretic peptide receptors type-A and
type-B. There receptors, also referred to as particulate GCsNO-stimulated cGMP production by isolated sGC with varying concentrations of GTP
Figure 5. Activity of compound 10 in rat cerebellum. Compound 10 inhibits cGMP
production induce by NMDA in rat cerebellar slices at 100 lM. Results are
means ± SEM (n = 3); *p <0.02, **p <0.001 versus NMDA control (2-sample t-test).
Figure 6. Binding of compound 10 to sGCcat. Compound 10 binds to the catalytic
domain of sGC (KD = 11.4 ± 1.8). (a) SPR sensorgram and (b) dose–response of
compound 10 binding to sGCcat.
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extracellular domain of the receptors, leading to an increase in
GTP turnover at the intracellular GC domain.32–34 In this study
we observed by SPR that compound 10 bound to the catalytic
domain of sGC in a 1:1 ratio. Inhibition of particulate GC was also
observed and supported the hypothesis of interaction at the cat-
alytic domain. Binding of compound 10 to an allosteric site that
is also capable of binding ATP could suggest these compounds
might also act on other ATP- and cyclic-nucleotide—binding
domains. We tested compound 10 against adenylyl cyclase, an
enzyme that converts ATP into cAMP, and it showed no activity
on basal or forskolin-stimulated adenylyl cyclase (data not shown).
However, activity against kinases or phosphodiesterases was not
investigated.
Activity of compound 10 in rat brain tissue highlights the
potential to use this new class of allosteric sGC inhibitors to studythe role of the NO—sGC—cGMP signalling pathway in the brain.
Reducing amounts of cGMP in cells would have implications in
downstream signalling proteins, such as cGMP-dependent protein
kinases and phosphodiesterases.354. Conclusion
We have identified a new type of small molecule inhibitors of
sGC, which are thought to be the first class to act through allosteric
regulation of the enzyme catalytic domain, rather than oxidation of
the haem or through the purine p-site.36 It is possible that the inhi-
bitors presented bind to the catalytic domain of sGC inducing a
conformational change, or ‘locking’ the enzyme in a basal confor-
mation, that is not favourable to activation by NO or GTP binding.
The inhibitor also inhibits particulate GC but not the related adeny-
late cyclase. Compound 10 (D12), with an IC50 and KD in the micro-
molar range, may be used as a new tool to inhibit the NO—sGC—
cGMP signalling pathway, and further study its implications and
regulatory functions in the brain.
5. Experimentals
Full-length human recombinant guanylyl cyclase (soluble) and
bovine lung guanylyl cyclase (soluble) were obtained from Enzo
lifesciences (catalogue numbers ALX-201-177 and ALX-202-039-
C005). Biacore consumables were purchased from GE Healthcare
(UK), including buffer stock solutions. All other reagents used were
obtained from Sigma. Starting materials were either commercially
available or synthesized according to methods reported in the lit-
erature. 1H and 13C NMR spectra were recorded on a Bruker
AMX-300 or a Bruker AMX-500 spectrometer. Chemical shifts are
reported as ppm relative to TMS internal standard. Mass spectra
were recorded on a Fisons VG70-SE spectrometer (EI, FAB) or an
Agilent 6100 Series LC-mass spectrometer using C-18 or C-4
columns. Microwave reactions were carried out using a CEM
Discover microwave.
5.1. Surface plasmon resonance
Surface plasmon resonance (SPR) experiments were performed
with a Biacore T200 instrument at 25 C. Data processing and anal-
ysis were performed using BIAevaluation software and Scrubber2.
All sensorgrams were double referenced by subtracting the
response in a reference flowcell and a blank sample. Materials
and methods used were the same as previously published.24
5.2. Soluble guanylate cyclase assay
In general, bovine lung soluble guanylyl cyclase (5 ng/ml) was
incubated with 50 mM Tris, 0.3 mM MgCl, 100 lM EGTA, 0.045%
BSA, and 1000 units/mL SOD at pH 7.4 and 1 mM MgGTP at
37 C. Compounds were added at 100 lM prior to adding the NO
donor DEA/NO (30 nM) or clamped NO concentrations. cGMP
generation was allowed to proceed for two minutes, after which
aliquots were withdrawn and inactivated by boiling in 50 mM
Tris, 4 mM EDTA buffer. cGMP formation was measured by a
standard radioimmunoassay.
5.3. Particulate guanylate cyclase assay
Purified rat lung membranes (20 lg protein/200 lL) were incu-
bated in Tris buffer with 10 mM phosphocreatine, 10 units/mL cre-
atine phosphokinase, and 10 lM ODQ to inhibit NO-activated GC.
The reaction took place with 0.3 mM MgCl, 0.5 mM MgATP, and
1 mM MgGTP, at 37 C. The compound was added and 1 lM ANP
5308 F. Mota et al. / Bioorg. Med. Chem. 23 (2015) 5303–5310used to activate pGC. cGMP formation was allowed to
proceed for 10.5 –12.5 min and was subsequently measured by
radioimmunoassay.
5.4. cGMP measurement in rat cerebellar slices
Brain slices methods were conducted as described in detail.37,38
Briefly, 0.4 mm thick sagittal cerebellar slices from 10-day-old ani-
mals were cut using a McIlwain tissue chopper. Experiments were
carried out in the presence of the broad spectrum phosphodi-
esterase inhibitor IBMX (1 mM; 10 min preincubation) and, when
appropriate, antagonists were added 10 min prior to IBMX.
Following treatment, brain slices were inactivated in boiling
Tris–HCl buffer (50 mM, pH 7.5) containing EDTA (4 mM) and
homogenised by sonication after which aliquots were removed
for measurement of protein (bicinchoninic acid method) and
cGMP (radioimmunoassay).
5.5. Virtual screening
Similarity searching using MACCS fingerprints at 85% and
75% Tanimoto similarity was performed in 2007 using the
following databases: Abinitio, Acros, Actimol, Akos/Akl, Akox/
Akx, Akos/Owh, Asinex, Chembridge, Chemstar, LifeChemicals,
MoscowMedChemLabs, Pharmeks, Sigma, SPECS, Vitas/Dah, Vitas/
Stk. The available structures were selected by hand based upon
diversity, molecular size, and apparent availability.
5.6. Molecular modelling
Docking was performed using the software Gold 5.1. The pdb
file (3uvj) was imported and analysed, and missing residue side
chains were added to the structure. The binding site was selected
by importing a list of residues correspondent to the allosteric bind-
ing site. The fitness function selected was GOLDSCORE and the
genetic algorithm search was performed at medium speed.
Results were visualised in CCG MOE software.
5.7. Synthesis
5.7.1. General synthesis of 2,3-dichloroquinoxalines 12
A solution of oxalic acid in 4 N HCl (5 mL) was added to a stir-
ring solution of the diamine (1:1) in 4 N HCl (15 mL) and the reac-
tion mixture was refluxed for 2 h. The solution was cooled to room
temperature and the precipitate filtered by suction, washed with
water and freeze-dried. The resulting 2,3-dihydroxyquinoxaline
11 was dissolved in thionyl chloride (5 mL). A catalytic amount
of N,N-dimethylformamide (0.01 equiv) was added to the solution
which was stirred under reflux for 2 h. The reaction mixture was
cooled to room temperature and concentrated under vacuum.
Water (10 mL) was added to the solid on an ice bath and the slurry
was stirred for 30 min at room temperature, after which the solid
was filtered and washed with water. The precipitate was taken
up in a minimum amount of DCM and filtered through a silica col-
umn and eluted with DCM.
5.7.2. 2,3-Dichloro-N-methylquinoxaline-6-carboxamide 13
Methylamine solution (33 wt % in absolute ethanol, 256 lL) was
added to DCM (3 mL) on ice and the resulting mixture was added
to a solution of 2,3-dichloroquinoxaline-6-carbonyl chloride
(261 mg, 1 mmol) in DCM (3 mL) whilst stirring at room tempera-
ture. The mixture was stirred at room temperature overnight after
which it was diluted with DCM (10 mL) and washed with saturated
sodium bicarbonate (3  10 mL) and brine (3  10 mL). The organ-
ics were dried over MgSO4, filtered, and the solved evaporated. The
crude compound was purified by flash column chromatographyusing a gradient of 30–60% ethyl acetate in cyclohexane to yield
the named compound as a white powder (89 mg, 35%). 1H NMR
(500 MHz, d6-DMSO) d: 8.84 (s, 1H, NH), 8.48 (s, 1H, ArH), 8.29
(d, J = 8.6 Hz, 1H, ArH), 8.14 (d, J = 8.6 Hz, 1H, ArH), 2.85 (d,
J = 3.7 Hz, 3H, CH3). 13C NMR (126 MHz, d6-DMSO) d: 165.0 (ArC),
146.0 (ArC), 145.6 (ArC), 141.1 (ArC), 139.6 (ArC), 136.8 (ArC),
129.9 (ArCH), 128.1 (ArCH), 126.6 (ArCH), 26.5 (CH3). MS-EI (m/
z): [M] calculated for C10H7Cl2N3O, 256.089; found 255.90.5.7.3. General synthesis of compounds 10 and 14–29
The quinoxaline and aniline (1:4) were transferred into a 10 mL
microwave vial containing a stirrer bar and NMP (1 mL). The mix-
ture was stirred at 160 C for 5 min under microwave irradiation.
The residue was taken up in water (5 mL) and extracted with
ethyl acetate (3  5 mL). The organics were washed with water
(3  5 mL) and brine (3  5 mL), dried over Mg2SO4, filtered and
concentrated in vacuo. The final compound was purified by flash
column chromatography.5.7.3.1. 4,40-((6-Nitroquinoxaline-2,3-diyl)bis(azanediyl))diphe-
nol 10. 1H NMR (500 MHz, d6-DMSO) d: 9.37 (s, 1H, OH), 9.31
(s, 1H, OH), 9.26 (s, 1H, NH), 9.07 (s, 1H, NH), 8.18 (d, J = 2.5 Hz, 1H,
ArH), 8.01 (dd, J = 8.9, 2.5 Hz, 1H, ArH), 7.64 (dd, J = 10.9, 8.9 Hz, 4H,
4  ArH), 7.51 (d, J = 8.9 Hz, 1H, ArH), 6.83 (d, J = 8.9 Hz, 4H,
4  ArH). 13C NMR (126 MHz, d6-DMSO) d 154.2 (ArC), 153.8
(ArC), 143.2 (ArC), 142.6 (ArC), 141.5 (ArC), 140.6 (ArC), 135.3
(ArC), 130.7 (ArC), 130.3 (ArC), 125.4 (ArCH), 123.7 (ArCH), 123.2
(ArCH), 120.1 (ArCH), 118.6 (ArCH), 115.5 (ArCH), 115.2 (ArCH).
HRMS-ES (m/z): [M+H]+ calculated for C20H16N5O4, 390.1202;
found, 390.1205.
5.7.3.2. 3,30-((6-Nitroquinoxaline-2,3-diyl)bis(azanediyl))diphe-
nol 14. 1H NMR (500 MHz, d6-DMSO) d: 9.50 (s, 1H, OH), 9.48
(s, 1H, OH), 9.41 (s, 1H, NH), 9.24 (s, 1H, NH), 8.32 (d, J = 2.6 Hz, 1H,
ArH), 8.11 (dd, J = 9.0, 2.6 Hz, 1H, ArH), 7.66 (d, J = 2.0 Hz, 1H, ArH),
7.64 (d, J = 9.0 Hz, 1H, ArH), 7.51 (t, J = 7.3 Hz, 1H, ArH), 7.27 (dd,
J = 18.4, 8.0 Hz, 2H, 2  ArH), 7.22–7.16 (m, 2H, 2  ArH), 6.54
(ddd, J = 17.0, 8.0, 1.5 Hz, 2H, 2  ArH). 13C NMR (126 MHz, d6-
DMSO) d: 155.89, 155.55, 143.29, 143.23, 142.52, 141.43, 135.29,
132.27, 131.87, 125.53, 123.46, 122.95, 120.18, 118.80, 113.95,
55.25, 55.22. HRMS-ES (m/z): [M+H]+ calculated for C22H16N5O4,
390.1202; found, 390.1189.
5.7.3.3. N2,N3-Bis(4-methoxyphenyl)-6-nitroquinoxaline-2,3-
diamine 15. 1H NMR (500 MHz, d6-DMSO) d: 9.39 (s, 1H,
NH), 9.20 (s, 1H, NH), 8.21 (d, J = 2.6 Hz, 1H, ArH), 8.04 (dd,
J = 8.9, 2.6 Hz, 1H, ArH), 7.82–7.74 (m, 4H, ArH), 7.54 (d,
J = 8.9 Hz, 1H, ArH), 7.05–6.99 (m, 4H, ArH), 3.78 (s, 6H,
2  OCH3). 13C NMR (126 MHz, d6-DMSO) d 155.9 (ArC), 155.6
(ArC), 143.3 (ArC), 143.2 (ArC), 142.5 (ArC), 141.4 (ArC), 135.3
(ArC), 132.3 (ArC), 131.9 (ArC), 125.5 (ArCH), 123.5 (ArCH), 122.9
(ArCH), 120.2 (ArCH), 118.8 (ArCH), 113.9 (ArCH), 55.3 (OCH3),
55.2 (OCH3). HRMS-ES (m/z): [M+H]+ calculated for C22H20N5O4,
418.1515; found, 418.1531.
5.7.3.4. 6-Nitro-N2,N3-diphenylquinoxaline-2,3-diamine
16. 1H NMR (500 MHz, d6-DMSO) d: 9.51 (s, 1H, NH), 9.34
(s, 1H, NH), 8.27 (d, J = 2.2 Hz, 1H, ArH), 8.07 (dd, J = 8.8, 2.2 Hz,
1H, ArH), 7.95–7.85 (m, 4H, 4  ArH), 7.62 (d, J = 8.8 Hz, 1H, ArH),
7.47–7.39 (m, 4H, 4  ArH), 7.20–7.09 (m, 2H, 2  ArH). 13C NMR
(126 MHz, d6-DMSO) d: 143.7 (ArC), 143.1 (ArC), 142.4 (ArC),
141.2 (ArC), 139.4 (ArC), 139.1 (ArC), 135.2 (ArC), 128.8 (ArCH),
125.9 (ArCH), 123.9 (ArCH), 123.4 (ArCH), 121.6 (ArCH), 121.1
(ArCH), 120.5 (ArCH), 119.2 (ArCH). HRMS-ES (m/z): [M+H]+ calcu-
lated for C20H16N5O2, 358.1304; found, 358.1305.
F. Mota et al. / Bioorg. Med. Chem. 23 (2015) 5303–5310 53095.7.3.5. N,N0-(((6-Nitroquinoxaline-2,3-diyl)bis(azanediyl))bis(4,
1-phenylene))diacetamide 17. 1H NMR (500 MHz, d6-DMSO)
d: 9.97 (s, 1H, NH), 9.96 (s, 1H, NH), 9.52 (s, 1H, NH), 9.33 (s, 1H,
NH), 8.28 (d, J = 2.4 Hz, 1H, ArH), 8.06 (dd, J = 8.9, 2.4 Hz, 1H,
ArH), 7.83 (dd, J = 13.6, 8.9 Hz, 4H, 4  ArH), 7.67–7.57 (m, 5H,
5  ArH), 2.05 (d, J = 4.9 Hz, 6H, 6  ArH). 13C NMR (126 MHz, d6-
DMSO) d: 168.1 (Ar-NH-CO-CH3), 168.0 (Ar-NH-CO-CH3), 143.5
(ArC), 143.1 (ArC), 142.3 (ArC), 141.3 (ArC), 135.5 (ArC), 135.3
(ArC), 134.5 (ArC), 134.1 (ArC), 125.7 (ArCH), 122.1 (ArCH), 121.6
(ArCH), 120.4 (ArCH), 119.4 (ArCH), 119.3 (ArCH), 118.9 (ArCH),
23.9 (Ar-NH-CO-CH3). HRMS-ES (m/z): [M+H]+ calculated for
C24H22N7O4, 472.1733; found, 472.1750.5.7.3.6. N,N0-(((6-Nitroquinoxaline-2,3-diyl)bis(azanediyl))bis(3,
1-phenylene))diacetamide 18. 1H NMR (500 MHz, d6-DMSO)
d 10.02 (s, 2H, 2  NH), 9.62 (s, 1H, NH), 9.44 (s, 1H, NH), 8.46–8.32
(m, 3H, 3  ArH), 8.12 (dd, J = 8.8, 2.0 Hz, 1H, ArH), 7.71–7.60 (m,
3H, ArH), 7.36–7.25 (m, 5H, 5  ArH), 2.09 (s, 3H, CH3), 2.08 (s,
3H, CH3). 13C NMR (126 MHz, d6-DMSO) d 168.4 (Ar-NHCOCH3),
139.7 (ArC), 135.1 (ArC), 128.8 (ArCH), 125.9 (ArCH), 120.6 (ArC),
119.2 (ArCH), 116.3 (ArCH), 115.8 (ArCH), 114.5 (ArCH), 114.1
(ArCH), 112.2 (ArCH), 111.6 (ArC), 109.1 (ArC), 24.1 (Ar-
NHCOCH3). HRMS-ES (m/z): [M+H]+ calculated for C24H22N7O4,
472.1733; found, 472.1733.
5.7.3.7. N2,N3-Bis(4-fluorophenyl)-6-nitroquinoxaline-2,3-di-
amine 19. 1H NMR (500 MHz, d6-DMSO) d: 9.52 (s, 1H),
9.36 (s, 1H), 8.27 (d, J = 2.4 Hz, 1H), 8.07 (dd, J = 8.9, 2.4 Hz, 1H),
7.92 (ddd, J = 13.8, 8.9, 5.0 Hz, 4H), 7.60 (d, J = 8.9 Hz, 1H), 7.31–
7.23 (m, 4H). HRMS-ES (m/z): [M+H] calculated for C20H14N5O3F2,
394.1116; found, 394.1123.
5.7.3.8. 4,40-(Quinoxaline-2,3-diylbis(azanediyl))diphenol
20. 1H NMR (500 MHz, d6-DMSO) d 9.21 (s, 2H, 2  OH),
8.71 (s, 2H, 2  NH), 7.61 (d, J = 8.7 Hz, 4H, 4  ArH), 7.42 (dt,
J = 7.3, 3.4 Hz, 2H, 2  ArH), 7.23 (dd, J = 6.1, 3.4 Hz, 2H, 2  ArH),
6.79 (d, J = 8.7 Hz, 4H, 4  ArH). 13C NMR (126 MHz, d6-DMSO) d
153.2 (ArC), 141.4 (ArC), 136.2 (ArC), 131.5 (ArC), 125.0 (ArCH),
124.4 (ArCH), 122.8 (ArCH), 115.1 (ArCH). HRMS-ES (m/z): [M
+H]+ calculated for C20H17N4O2, 345.1352; found, 345.1347.
5.7.3.9. 4,40-((6-(Trifluoromethyl)quinoxaline-2,3-diyl)bis(aza-
nediyl))diphenol 21. 1H NMR (500 MHz, d6-DMSO) d: 9.34
(s, 1H, OH), 9.32 (s, 1H, OH), 9.03 (s, 1H, NH), 8.96 (s, 1H, NH),
7.68 (s, 1H, ArH), 7.65–7.59 (m, 4H, 4  ArH), 7.55 (d, J = 8.5 Hz,
1H, ArH), 7.47 (dd, J = 8.5, 1.8 Hz, 1H, ArH), 6.84–6.78 (m, 4H,
4  ArH). 13C NMR (126 MHz, d6-DMSO) d: 170.3 (ArC), 153.8
(ArC), 153.6 (ArC), 142.8 (ArC), 142.3 (ArC), 138.7 (ArC), 135.7
(ArC), 131.0 (ArC), 130.8 (ArC), 125.8 (ArCH), 123.4 (ArCH), 123.2
(ArCH), 121.9 (ArCH), 119.9 (ArCH), 115.2 (ArCH). HRMS-CI (m/z):
[M+H]+ calculated for C21H16F3N4O2, 413.12199; found,
413.120133.
5.7.3.10. 3,30-((6-(Trifluoromethyl)quinoxaline-2,3-diyl)bis(aza-
nediyl))diphenol 22. 1H NMR (500 MHz, d6-DMSO) d: 9.49 (s,
1H, OH), 9.46 (s, 1H, OH), 9.18 (s, 1H, NH), 9.12 (s, 1H, NH), 7.81 (s,
1H, ArH), 7.67 (d, J = 8.4 Hz, 1H, ArH), 7.61–7.56 (m, 2H, 2  ArH),
7.50 (d, J = 2.5 Hz, 1H, ArH), 7.26 (dd, J = 11.6, 9.0 Hz, 2H,
2  ArH), 7.18 (td, J = 8.4, 2.5 Hz, 2H, 2  ArH), 6.57–6.46 (m, 2H,
2  ArH). 13C NMR (126 MHz, d6-DMSO) d: 157.6 (ArC), 142.5
(ArC), 142.0 (ArC), 140.7 (ArC), 138.5 (ArC), 135.5 (ArC), 129.3
(ArCH), 126.2 (ArCH), 123.5 (ArC), 122.3 (ArCH), 120.6 (ArC),
112.0 (ArCH), 111.7 (ArCH), 110.5 (ArCH), 110.2 (ArCH), 108.3
(ArCH), 108.0 (ArCH). HRMS-CI (m/z): [M+H]+ calculated for
C21H16F3N4O2, 413.12199; found, 413.121732.5.7.3.11. 2,3-Bis((4-hydroxyphenyl)amino)quinoxaline-6-car-
bonitrile 23. 1H NMR (500 MHz, d6-DMSO) d: 9.76 (s, 1H,
OH), 9.73 (s, 1H, OH), 9.56 (s, 1H, NH), 9.43 (s, 1H, NH), 8.25 (s,
1H, ArH), 8.04 (dt, J = 8.8, 3.2 Hz, 4H, 4  ArH), 7.93 (ddd, J = 11.1,
8.3, 2.3 Hz, 2H, 2  ArH), 7.24 (dt, J = 8.8, 3.2 Hz, 4H, 4  ArH). 13C
NMR (126 MHz, d6-DMSO) d: 153.9 (ArC), 153.7 (ArC), 142.9
(ArC), 142.3 (ArC), 139.6 (ArC), 136.0 (ArC), 130.8 (ArC), 130.5
(ArC), 129.3 (ArCH), 126.5 (ArCH), 125.9 (ArCH), 123.6 (ArCH),
123.2 (ArCH), 119.5 (ArC-CN), 115.19 (ArCH), 115.17 (ArCH),
105.6 (ArC-CN). HRMS-CI (m/z): [M+H]+ calculated for
C21H16N5O2, 370.13040; found, 370.129541.
5.7.3.12. 2,3-Bis((3-hydroxyphenyl)amino)quinoxaline-6-car-
bonitrile 24. 1H NMR (500 MHz, d6-DMSO) d: 9.47 (s, 1H,
OH), 9.42 (s, 1H, OH), 9.27 (s, 1H, NH), 9.16 (s, 1H, NH), 7.93 (d,
J = 1.7 Hz, 1H, ArH), 7.66–7.57 (m, 2H, 2  ArH), 7.53 (s, 1H, ArH),
7.49 (s, 1H, ArH), 7.30–7.24 (m, 2H, 2  ArH), 7.18 (dd, J = 14.3,
8.0 Hz, 2H, 2  ArH), 6.57–6.47 (m, 2H, 2  ArH). 13C NMR
(126 MHz, d6-DMSO) d: 157.6 (ArC), 142.6 (ArC), 142.0 (ArC),
140.6 (ArC), 140.3 (ArC), 139.3 (ArC), 135.8 (ArC), 129.7 (ArCH),
129.3 (ArCH), 127.0 (ArCH), 126.3 (ArCH), 119.3 (Ar-C), 112.1
(ArCH), 111.8 (ArCH), 110.8 (ArCH), 110.4 (ArCH), 108.4 (ArCH),
108.1 (ArCH), 106.4 (ArC-CN). HRMS-CI (m/z): [M+H]+ calculated
for C21H16N5O2, 370.13040; found, 370.129114.
5.7.3.13. 4,40-((6-Chloroquinoxaline-2,3-diyl)bis(azanediyl))
diphenol 25. 1H NMR (500 MHz, d6-DMSO) d: 9.24 (s, 1H),
9.23 (s, 1H), 8.87 (s, 1H), 8.81 (s, 1H), 7.65–7.55 (m, 4H), 7.45–
7.37 (m, 2H), 7.22 (dt, J = 8.6, 2.1 Hz, 1H), 6.83–6.76 (m, 4H). 13C
NMR (126 MHz, d6-DMSO) d: 153.51 (ArC), 153.45 (ArC), 141.97
(ArC), 141.61 (ArC), 137.03 (ArC), 134.97 (ArC), 131.18 (ArC),
131.09 (ArC), 128.04 (ArC), 126.35 (ArCH), 124.25 (ArCH), 123.73
(ArCH), 123.07 (ArCH), 123.04 (ArCH), 115.14 (ArCH). HRMS-ES
(m/z): [M+H] calculated for C20H16N4O2Cl, 379.0962; found,
379.0927.
5.7.3.14. 3,30-((6-Chloroquinoxaline-2,3-diyl)bis(azanediyl))
diphenol 26. 1H NMR (500 MHz, d6-DMSO) d: 9.39 (s, 2H),
9.03 (s, 1H), 8.98 (s, 1H), 7.58–7.49 (m, 3H), 7.48 (s, 1H), 7.33
(dd, J = 8.7, 2.3 Hz, 1H), 7.23 (s, 2H), 7.16 (td, J = 8.0, 1.7 Hz, 2H),
6.50 (d, J = 8.0 Hz, 2H). 13C NMR (126 MHz, d6-DMSO) d: 157.58
(ArC), 141.66 (ArC), 141.25 (ArC), 140.92 (ArC), 140.83 (ArC),
136.82 (ArC), 134.79 (ArC), 129.22 (ArCH), 128.78 (ArC), 126.72
(ArCH), 125.03 (ArCH), 124.05 (ArCH), 111.55 (ArCH), 110.06
(ArCH), 107.83 (ArCH). HRMS-ES (m/z): [M+H] calculated for
C20H16N4O2Cl, 379.0962; found, 379.0940.
5.7.3.15. 2,3-Bis((4-hydroxyphenyl)amino)-N-methylquinoxa-
line-6-carboxamide 27. 1H NMR (500 MHz, d6-DMSO) d
9.26 (s, 1H, OH), 9.25 (s, 1H, OH), 8.89 (s, 1H, Ar-NH), 8.82 (s, 1H,
Ar-NH), 8.44 (q, J = 4.5 Hz, 1H, Ar-CONHCH3), 7.94 (d, J = 2.0 Hz,
1H, ArH), 7.71 (dd, J = 8.4, 2.0 Hz, 1H, ArH), 7.63 (d, J = 8.4 Hz, 4H,
4  ArH), 7.43 (d, J = 8.4 Hz, 1H, ArH), 6.86–6.77 (m, 4H, 4  ArH),
2.77 (d, J = 4.5 Hz, 3H, Ar-CONHCH3). 13C NMR (126 MHz, d6-
DMSO) d 166.5 (Ar-CONHCH3), 153.5 (ArC), 153.4 (ArC), 142.2
(ArC), 141.9 (ArC), 138.2 (ArC), 137.2 (ArC), 135.4 (ArC), 131.3
(ArC), 131.1 (ArC), 130.0 (ArCH), 124.6 (ArCH), 123.8 (ArCH),
123.1 (ArCH), 115.1 (ArCH), 26.3 (Ar-CONHCH3). HRMS-EI (m/z):
[M] calculated for C22H19N5O3, 401.1488; found, 401.1481.
5.7.3.16. 6,7-Bis((3-hydroxyphenyl)amino)-N-methyl-2-naph-
thamide 28. 1H NMR (500 MHz, d6-DMSO) d 9.42 (s, 1H,
OH), 9.41 (s, 1H, OH), 9.04 (s, 1H, NH), 8.98 (s, 1H, NH), 8.51 (d,
J = 4.4 Hz, 1H, Ar-CONHCH3), 8.06 (s, 1H, ArCH), 7.80 (d,
J = 8.4 Hz, 1H, ArCH), 7.55 (d, J = 8.4 Hz, 1H, ArCH), 7.50 (d,
J = 12.0 Hz, 2H, 2  ArCH), 7.28 (d, J = 8.0 Hz, 2H, 2  ArCH), 7.17
5310 F. Mota et al. / Bioorg. Med. Chem. 23 (2015) 5303–5310(t, J = 8.0 Hz, 2H, 2  ArCH), 6.50 (d, J = 8.0 Hz, 2H, 2  ArCH), 2.80
(d, J = 4.4 Hz, 3H, Ar-CONHCH3). 13C NMR (126 MHz, d6-DMSO) d
166.5 (Ar-CONHCH3), 157.6 (ArC), 157.6 (ArC), 141.9 (ArC), 141.6
(ArC), 141.0 (ArC), 140.9 (ArC), 137.9 (ArC), 135.3 (ArC), 130.8
(ArCH), 129.22 (ArCH), 129.19 (ArCH), 124.9 (ArC), 124.3 (ArC),
123.7 (ArC), 111.7 (ArCH), 111.6 (ArCH), 110.2 (ArCH), 110.0
(ArCH), 108.0 (ArCH), 107.9 (ArCH), 26.3 (Ar-CONHCH3). HRMS-EI
(m/z): [M] calculated for C22H19N5O3, 401.1488; found, 401.1479.5.7.4. 4,40-((6-Aminoquinoxaline-2,3-diyl)bis(azanediyl))diphenol
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Tin(II) chloride dihydrate (112.5 mg, 0.5 mmol) was added to a
solution of 4,40-((6-nitroquinoxaline-2,3-diyl)bis(azanediyl))diphe
nol 10 (39 mg, 0.1 mmol) in ethanol (15 mL) and the resulting mix-
ture was brought to boil. A solution of sodium borohydride
(18.9 mg, 0.5 mmol) in ethanol (5 mL) was added to the boiling
mixture dropwise and refluxed for 1.5 h. Upon cooling, water
(10 mL) was added. Sodium hydroxide was added until neutralisa-
tion of the solution. The ethanol was evaporated from the mixture
and an extraction with ethyl acetate (20 mL) was performed. The
organics were washed with brine (3  10 mL) and dried over mag-
nesium sulfate, filtered and the solvent evaporated under reduced
pressure. The crude material was purified by flash column chro-
matography using a gradient of 50–80% ethyl acetate in cyclohex-
ane to give the named compound (22.0 mg, 61%). 1H NMR
(500 MHz, d6-DMSO) d: 9.13 (s, 1H, OH), 9.06 (s, 1H, OH), 8.47 (s,
1H, NH), 8.23 (s, 1H, NH), 7.60 (d, J = 8.9 Hz, 2H, 2  ArH), 7.53
(d, J = 8.9 Hz, 2H, 2  ArH), 7.15 (d, J = 8.6 Hz, 1H, ArH), 6.75 (dd,
J = 10.8, 8.9 Hz, 4H, 4  ArH), 6.64 (dd, J = 8.6, 2.4 Hz, 1H, ArH),
6.58 (d, J = 2.4 Hz, 1H, ArH), 5.06 (s, 2H, NH2). 13C NMR
(126 MHz, d6-DMSO) d: 152.8 (ArC), 152.4 (ArC), 146.3 (ArC),
141.4 (ArC), 138.5 (ArC), 137.6 (ArC), 132.5 (ArC), 132.0 (ArC),
128.4 (ArC), 125.4 (ArCH), 122.4 (ArCH), 121.8 (ArCH), 115.0
(ArCH), 114.99 (ArCH), 114.8 (ArCH), 106.5 (ArCH). HRMS-CI (m/
z): [M+H]+ calculated for C20H18N5O2, 360.1460; found, 360.1451.Acknowledgement
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